866-997-4948(US-Canada Toll Free)

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 22 Pages

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Heat Shock Protein 75 kDa Mitochondrial - Pipeline Review, H1 2017'; Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Heat shock protein 75 kDa mitochondrial is a protein that is encoded by the TRAP1 gene. It is a negative regulator of mitochondrial respiration able to modulate the balance between oxidative phosphorylation and aerobic glycolysis. This protein may function in regulating cellular stress responses.

The report 'Heat Shock Protein 75 kDa Mitochondrial - Pipeline Review, H1 2017' outlays comprehensive information on the Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Genetic Disorders which include indications Glioblastoma Multiforme (GBM), Metastatic Brain Tumor and Neurofibromatoses Type II.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1)
- The report reviews Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Overview
Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Companies Involved in Therapeutics Development
Plex Pharmaceuticals Inc
Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Drug Profiles
Panvotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Hsp90 and TRAP1 for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Hsp90 and TRAP1 for Metastatic Brain Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SMTIN-P01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Plex Pharmaceuticals Inc, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Molecule Type, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *